(YMAB) Y mAbs Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9842411095
YMAB: Cancer, Antibody, Vaccine, Monoclonal, Therapeutic
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of antibody-based therapeutic products for cancer treatment. The companys lead product, DANYELZA, is a monoclonal antibody approved for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. DANYELZA is administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is also investigating DANYELZA for second-line relapsed osteosarcoma in a Phase II clinical study.
Y-mAbs pipeline includes GD2-SADA, a product in Phase I clinical trial for GD2 positive solid tumors, and Omburtamab, a murine monoclonal antibody targeting central nervous system/leptomeningeal metastases from neuroblastoma. The company is leveraging its SADA (Snakebite Antidote Divine Antisoma) PRIT (Precision Rituximab) technology platform to enhance therapeutic outcomes. Additionally, it is developing CD38-SADA and GD2-GD3 Vaccine candidates. Y-mAbs has strategic partnerships with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to advance its product portfolio.
Founded in 2015 and headquartered in New York, New York, Y-mAbs operates in the biotechnology sector, focusing on innovative cancer treatments. The companys commercialization efforts are supported by its collaborations with leading research institutions. For more information, visit their website at https://www.ymabs.com.
Additional Sources for YMAB Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
YMAB Stock Overview
| Market Cap in USD | 237m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2018-09-21 |
YMAB Stock Ratings
| Growth 5y | -76.7% |
| Fundamental | -34.9% |
| Dividend | 0.0% |
| Rel. Strength Industry | -66.3 |
| Analysts | 4.27/5 |
| Fair Price Momentum | 3.20 USD |
| Fair Price DCF | - |
YMAB Dividends
No Dividends PaidYMAB Growth Ratios
| Growth Correlation 3m | -94.6% |
| Growth Correlation 12m | -69.9% |
| Growth Correlation 5y | -70.8% |
| CAGR 5y | -23.17% |
| CAGR/Max DD 5y | -0.24 |
| Sharpe Ratio 12m | -1.97 |
| Alpha | -81.74 |
| Beta | 1.34 |
| Volatility | 77.78% |
| Current Volume | 208.4k |
| Average Volume 20d | 332k |
As of March 16, 2025, the stock is trading at USD 4.67 with a total of 208,448 shares traded.
Over the past week, the price has changed by -9.50%, over one month by -25.16%, over three months by -52.92% and over the past year by -68.87%.
Probably not. Based on ValueRay Fundamental Analyses, Y mAbs Therapeutics (NASDAQ:YMAB) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -34.90 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of YMAB as of March 2025 is 3.20. This means that YMAB is currently overvalued and has a potential downside of -31.48%.
Y mAbs Therapeutics has received a consensus analysts rating of 4.27. Therefor, it is recommend to buy YMAB.
- Strong Buy: 7
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 1
According to ValueRays Forecast Model, YMAB Y mAbs Therapeutics will be worth about 3.6 in March 2026. The stock is currently trading at 4.67. This means that the stock has a potential downside of -22.91%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 18 | 285.4% |
| Analysts Target Price | 20.4 | 336% |
| ValueRay Target Price | 3.6 | -22.9% |